LAUSANNE, Switzerland, May 15 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, announced the signature of a license agreement with its long-term European pharmaceutical partner, for the marketing of Salvacyl(R)/Moapar(R) 3-month formulation, a gonadotropin releasing hormone (GnRH) agonist analogue, effective in the treatment of severe sexual deviations in adult men by inducing and maintaining a reversible reduction of testosterone to castrate serum levels. Debiopharm has developed and received marketing authorisations for Salvacyl / Moapar in nine major European countries, including France, Germany, UK, Sweden, Norway, Denmark, Belgium, the Netherlands and Finland.
"There is a genuine unmet medical and social need for the treatment of sexual deviations. Not many pharma companies are willing or courageous enough to provide this type of treatment but we feel that we have a responsibility to help doctors and patients with the tools they need, even if it is difficult or controversial," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group.
In the treatment of sexual deviations in men, administration of Salvacyl(R)/Moapar(R) every 3 months is an advantage over daily oral forms or intra-muscular weekly injections required with antiandrogens such as cyproterone acetate (CPA) and medroxyprogesterone acetate (MPA) and there are fewer side effects.
Two studies have shown that regular injections of the active
ingredient, triptorelin, over a period of eight months to seven years in
male patients with sexual deviations demonstrated a good efficacy and
safety profile. Triptorelin produced reversible serum castrate testosterone
levels (defined as less than or equal to 1.735 nmol/L) in all patients, and
concurrently with the decrease in testosterone levels, triptorelin
|SOURCE The Debiopharm Group|
Copyright©2008 PR Newswire.
All rights reserved